In-Person Event Apr 14 - 16th
Paula Rio
Head of the Bone Marrow Aplasia Unit at CIEMAT/CIBERER/IIS-FJD, Universidad Autónoma in Madrid, Spain
Michel Sadelain
Founding Director of the new Columbia Initiative in Cell Engineering and Therapy (CICET) and Director of the Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center, USA
Alessia Cavazza
University College London, UK and UNIMORE, Italy
Anastasia Conti
San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Italy
Andrew Sewell
Cardiff University School of Medicine, UK
Andre Cohen
Bayer Pharmaceuticals, Germany
Ayal Hendel
Bar-Ilan University, Israel
Carla Fuster García
Institute for Transfusion Medicine and Gene Therapy, Universitätsklinikum Freiburg, Germany
Cecilia Jimenez-Mallebrera
Hospital Sant Joan de Déu Barcelona and CIBERER, Spain
Christian Grøndahl
SNIPR Biome
Francisco J. Sánchez-Rivera
Massachusetts Institute of Technology (MIT), USA
Giorgio Galli
Novartis Biomedical Research, Switzerland
Jakob Nilsson
Danish Cancer Institute, Denmark
Karim Benabdel Lah El Khlanji
University of Granada, Spain
Karina Thorn
Novo Nordisk, Denmark
Laura Torella
AstraZeneca, Sweden
Marcello Maresca
AstraZeneca, Sweden
Mathew Garnett
Wellcome Sanger Institute & Mosaic Therapeutics, UK
Manuel A.F.V. Gonçalves
University of Leiden, The Netherlands
Nerea Zabaleta
University of Navarra, Spain
Özcan Met
Herlev University Hospital and DTU, Denmark
Patrick Pausch
VU LSC-EMBL, Lithuania
Peter Haahr
University of Copenhagen, Denmark
Randal Platt
ETH Zurich, Switzerland
Roberta Esposito
University of Bern, Switzerland
Sean Semple
Acuitas Therapeutics, Canada
Stephan Kadauke
University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia (CHOP), USA
Amanda Haas
Agilent Technologies, USA
Ashley Jacobi
Integrated DNA Technologies, USA
TBD
Aldevron, USA
TBD
BioSpring, Germany
TBD
ST Pharm, South Korea
TBD
Lonza, Switserland
Rapolas Zilionis
Atrandi Biosciences, Lithuania